Current and Emerging Data on SGLT2 Inhibitors in Heart Failure

SGLT2 beyond diabetes

In this video, Prof Lars Lund, Professor of Medicine and Cardiology (Karolinska Institute, Stockholm, SE) discusses the emerging data on SGLT2 inhibitors.

Educational objectives

  • Understand the SGLT-2 inhibitor cardiovascular outcome trial (CVOT) data
  • Differentiate the latest guideline updates for the treatment of T2D and their recommendations regarding the importance of considering comorbidities, including atherosclerotic cardiovascular disease (ASCVD) and heart failure (HF).
  • Apply clinical and real-world evidence of the SGLT2 inhibitor class for use in prevention of hospitalisation in HF, as well as future ongoing studies in the treatment of HF
  • Assess the interrelationships linking diabetes, HF and CVD.
  • Interpret the potential cardio-renal mechanisms of the SGLT-2 inhibitor class in reducing the risk of CV, including HF. Evaluate emerging data of the treatment of HF with SGLT2 inhibitors in patients with or without T2DM.
Lars H Lund
Dr Lund's expertise is in HF big data and registry-based comparative outcomes studies and pragmatic trials. He is active in programs to improve utilisation of existing evidence-based interventions in heart failure with reduced ejection fraction, as well as in novel interventions.

 


Programme Outline
  • SGLT2 in HF now and the futureAndrew JS CoatsCarolyn Lam
  • DAPA-HF design and rationaleFelipe Martinez
  • SGLT2 beyond diabetesLars H Lund
  • Guidelines, data & future practicesScott SolomonAndrew JS Coats
  • DAPA-HF outcomesFrank Ruschitzka
  • Discussion with the DAPA-HF trialistJohn JV McMurrayMikhail Kosiborod
These videos were funded by an unrestricted educational grant from AstraZeneca.

SGLT2's - Guidelines, data & future practices